EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Sarcoidosis Treatment Patterns in the United States

Ruchika Sangani, Nicholas A Bosch, Praveen Govender, Brittany Scarpato, Allan J Walkey, Julia Newman, Anica C Law, Kari R Gillmeyer, Divya A Shankar

CHEST · 2025

DOI: 10.1016/j.chest.2024.10.040 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2025. Verfasst von Ruchika Sangani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Center, Boston University School of Medicine, Boston, MA; Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allerg…. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Sarcoidosis, Practice Patterns, Physicians', Adrenal Cortex Hormones. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, HSRD VA, Boston University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are limited US Food and Drug Administration-approved medications and real-world data on sarcoidosis treatment in the United States. Concordance of practice patterns with guideline recommendations have not been well characterized. RESEARCH QUESTION: What are the practice patterns and factors associated with treatment for patients with sarcoidosis in the year following diagnosis? STUDY DESIGN AND METHODS: A retrospective analysis was conducted of patients with sarcoidosis from 2016 to 2022 using a multicenter, all-payer claims database (TriNetX). Treatments with corticosteroids and/or nonsteroidal immunosuppressive medications (methotrexate, mycophenolate, leflunomide, hydroxychloroquine, cyclophosphamide, infliximab, adalimumab, azathioprine, rituximab, and Janus kinase inhibitors) within 1 year of diagnosis were ascertained. We summarized treatment rates and sequence of prescribed medications by mean rank, and used multivariable logistic regression analyses to identify factors associated with treatment. RESULTS: Of 13,330 patients with sarcoidosis meeting inclusion, 5,671 (42.5%) received treatment within 1 year of diagnosis. Of those treated, 60% received steroids alone, 13% received nonsteroidal immunosuppressives alone, and 27% received both. Furthermore, 25% of treated patients received a nonsteroidal immunosuppressive as their first medication. Corticosteroids had the lowest mean rank order, indicating they were, on average, the first medication initiated. Among those with pulmonary or cutaneous involvement, the second medication initiated, on average, was hydroxychloroquine; in those with cardiac or neurologic involvement, it was adalimumab and mycophenolate, respectively. Factors associated with higher odds of treatment were Black race, organ involvement at baseline (pulmonary, cardiac, and neurologic), and comorbid diagnoses (fatigue, hypercalcemia, and interstitial lung disease). INTERPRETATION: Within the first year of diagnosis, 43% of patients with sarcoidosis were started on treatment. Nonsteroidal immunosuppressives were used in 40% of treated patients. Although factors associated with treatment initiation aligned with guideline recommendations, practice patterns of treatment were variable, particularly in choice and sequence of nonsteroidal immunosuppressive therapy, underscoring the need for future trials and comparative effectiveness studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsSarcoidosisPractice Patterns, Physicians'Adrenal Cortex HormonesHumansUnited StatesRetrospective StudiesFemaleMaleMiddle AgedAdult

Stichwörter der Autor:innen

practice pattern researchsarcoidosistreatment of sarcoidosis

Substanzen

Immunosuppressive AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Pulmonary Center, Boston University School of Medicine, Boston, MA; Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, CA. Electroni…
  • Pulmonary Center, Boston University School of Medicine, Boston, MA.
  • University of Utah Health, Salt Lake City, UT.
  • UMass Chan Medical School, Health Systems Science, Worcester, MA.
  • Pulmonary Center, Boston University School of Medicine, Boston, MA; Center for Health Optimization & Implementation Research, VA Boston Healthcare System, Boston, MA.

Förderung

  • NHLBI NIH HHS
  • HSRD VA
  • Boston University
  • National Institutes of Health
  • National Heart Lung and Blood Institute Division of Intramural Research

Zitieren

APA

Sangani, R., Bosch, N. A., Govender, P., Scarpato, B., Walkey, A. J., Newman, J., Law, A. C., Gillmeyer, K. R., & Shankar, D. A. (2025). Sarcoidosis Treatment Patterns in the United States. CHEST. https://doi.org/10.1016/j.chest.2024.10.040

Vancouver

Sangani R, Bosch NA, Govender P, Scarpato B, Walkey AJ, Newman J, et al. Sarcoidosis Treatment Patterns in the United States. CHEST. 2025. doi:10.1016/j.chest.2024.10.040

BibTeX
@article{Sangani2025,
  author = {Sangani, Ruchika and Bosch, Nicholas A and Govender, Praveen and Scarpato, Brittany and Walkey, Allan J and Newman, Julia and Law, Anica C and Gillmeyer, Kari R and Shankar, Divya A},
  title = {Sarcoidosis Treatment Patterns in the United States},
  journal = {CHEST},
  year = {2025},
  doi = {10.1016/j.chest.2024.10.040}
}
Kostenlos starten →